“Initial results show promising recordings of nerve cell impulses,” Musk said in a post on the social media platform X on Monday. Impulses are the activity of neurons — cells that use bioelectric and chemical signals to send information to the brain and body — according to the National Institutes of Health.
Neuralink logo. Photo: Reuters
The U.S. Food and Drug Administration last year gave Neuralink permission to conduct its first human trial of the implantable device, a major milestone in the startup’s ambitions to help patients overcome paralysis and a range of neurological diseases.
In September 2023, Neuralink said it had received approval to recruit people to conduct human chip implant trials.
Using robots to surgically implant a brain-computer interface (BCI) implant into the brain region that controls movement, Neuralink said the company's initial intention was to enable people to control a mouse cursor or computer keyboard with just their thoughts.
Neuralink's first product will be called Telepathy, Musk said in a separate post on X.
The company was valued at about $5 billion last June, but four lawmakers in late November asked the US Securities and Exchange Commission to investigate whether Musk misled investors about the safety of the technology after veterinary records revealed problems related to the implant in monkeys, including paralysis, seizures and brain swelling.
Musk wrote in a social media post on September 10 that “no monkeys have died as a result of Neuralink implants.”
Mai Anh (according to Reuters)
Source
Comment (0)